Skip to content

Performance of the Freestyle Libre Version 2 isCGM in daily practice in Elderly

Performance of the Freestyle Libre Version 2 isCGM in daily practice in Elderly - Performance of the FreeStyle Libre glucose monitor (Ver. 2) in the elderly

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56777
Enrollment
26
Registered
2024-04-24
Start date
2024-03-03
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
65 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >=70 years at time of inclusion - Diabetes, type 1 or type 2 - Ability to provide oral and written informed consent

Exclusion criteria

Exclusion criteria: - A history of allergies towards patch substances/adhesive; - The inability to understand the Dutch language; - Oral or injected steroid use within the past 3 months - Uncontrolled thyroid disease or hypertension - Poor visual acuity - Inability or unwillingness to meet the protocol requirements, such as being incapacitated - Any severe or uncontrolled medical or psychological condition which, in the opinion of the investigator, would compromise the ability to meet protocol requirements.

Design outcomes

Primary

MeasureTime frame
Primary outcome is the accuracy of the FSL-v2 compared to Contour blue capillary measurement results during the 14-day study period.

Secondary

MeasureTime frame
Secondary outcomes are (i) the accuracy of the FSL during the standardized oral glucose load test and (ii) the usability and satisfaction with the FSL. Accuracy will be analysed as according to the guidelines for Integrated Continuous Glucose Monitoring Approvals (Class II-510(K), (Parkes) error grid-, bias (including MARD), correlation, stability and Bland-Altman analysis.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)